Clinical-stage biopharmaceutical company Hoth Therapeutics Inc (NASDAQ:HOTH) announced Wednesday that it has partnered with Washington University School of Medicine in St. Louis.

The collaboration is aimed at advancing Alzheimer's disease research through a novel therapeutic strategy. It focuses on a recently submitted NIH grant proposal focused on studying HT-ALZ, an FDA-approved NK-1 receptor antagonist, for its potential to reduce neuroinflammation and improve cognitive function in Alzheimer's disease.

Dr. Carla M. Yuede, professor in the Departments of Psychiatry, Neurology, and Neuroscience, and director of the Animal Behavior Core at Washington University, will lead the research collaboration.

Titled 'Cell Type Specificity of Neurokinin-1 Receptor Antagonists on Cognitive Improvement', the proposal aims to understand the precise neurological mechanisms and cellular targets responsible for the beneficial cognitive effects observed with HT-ALZ.